Semaglutide vs Tirzepatide: Complete Drug Class Comparison (2026)

Clinical trial data consistently shows tirzepatide produces greater weight loss than semaglutide. In the SURMOUNT trials, tirzepatide (Zepbound) achieved 20-22% body weight loss at the highest dose, compared to 15-17% with semaglutide (Wegovy) in the STEP trials. However, individual results vary significantly, and some patients respond better to semaglutide. The 'better' drug is the one that works for your body, that you can tolerate, and that you can afford.

Yes, switching between GLP-1 medications is common and generally safe when managed by your prescriber. If you have plateaued on semaglutide or are experiencing intolerable side effects, your doctor may recommend switching to tirzepatide. Most prescribers will start tirzepatide at a lower dose rather than jumping to an equivalent of your semaglutide dose, to reduce gastrointestinal side effects during the transition.

Tirzepatide activates two receptors — GLP-1 and GIP — while semaglutide activates only GLP-1. The GIP receptor activation adds additional metabolic benefits including improved insulin sensitivity and potentially different appetite-regulating pathways. This dual mechanism is believed to produce the greater weight loss and metabolic improvements seen in clinical trials. Think of it as attacking the problem from two angles instead of one.

Both drug classes share similar gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation. In clinical trials, tirzepatide had slightly higher rates of gastrointestinal side effects at the highest doses, but the difference was modest. Most side effects with either drug are worst during dose escalation and improve over time. Individual tolerance varies more than class-level differences.

List prices are comparable: Mounjaro and Zepbound (tirzepatide) run approximately $1,000-1,100/month, while Ozempic and Wegovy (semaglutide) cost $1,200-1,350/month. However, actual out-of-pocket costs depend heavily on insurance formulary placement and available savings programs. Eli Lilly and Novo Nordisk both offer manufacturer savings cards and patient assistance programs. Insurance coverage varies — some plans favor one over the other.

Semaglutide has a longer track record with more published data. Ozempic was FDA-approved in 2017 and Wegovy in 2021, giving semaglutide several more years of real-world evidence and long-term safety data. Tirzepatide (Mounjaro approved 2022, Zepbound 2023) is newer but its clinical trial program was robust and included the landmark SURMOUNT and SURPASS series. Both have extensive Phase 3 trial data supporting efficacy and safety.

As of early 2026, tirzepatide is available only as a subcutaneous injection (weekly). Eli Lilly has oral tirzepatide (orforglipron) in late-stage clinical trials, but it has not yet received FDA approval. By contrast, semaglutide already has an FDA-approved oral formulation — Rybelsus for diabetes and oral Wegovy for weight loss. If you prefer pills over injections, semaglutide currently has the advantage.